GB9301000D0 - Chemical compounds - Google Patents

Chemical compounds

Info

Publication number
GB9301000D0
GB9301000D0 GB939301000A GB9301000A GB9301000D0 GB 9301000 D0 GB9301000 D0 GB 9301000D0 GB 939301000 A GB939301000 A GB 939301000A GB 9301000 A GB9301000 A GB 9301000A GB 9301000 D0 GB9301000 D0 GB 9301000D0
Authority
GB
United Kingdom
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB939301000A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB939301000A priority Critical patent/GB9301000D0/en
Publication of GB9301000D0 publication Critical patent/GB9301000D0/en
Priority to IS4121A priority patent/IS4121A/is
Priority to ZA94335A priority patent/ZA94335B/xx
Priority to CN94191527A priority patent/CN1043997C/zh
Priority to PCT/EP1994/000145 priority patent/WO1994017090A1/en
Priority to AT94905100T priority patent/ATE164849T1/de
Priority to DE69409503T priority patent/DE69409503T2/de
Priority to CA002153688A priority patent/CA2153688A1/en
Priority to DK94905100T priority patent/DK0680488T3/da
Priority to EP94905100A priority patent/EP0680488B1/en
Priority to SK918-95A priority patent/SK281229B6/sk
Priority to PL94309975A priority patent/PL309975A1/xx
Priority to ES94905100T priority patent/ES2117249T3/es
Priority to KR1019950702963A priority patent/KR960700261A/ko
Priority to US08/446,727 priority patent/US5925624A/en
Priority to AU58851/94A priority patent/AU679714B2/en
Priority to RU95122754A priority patent/RU2129561C1/ru
Priority to JP51665294A priority patent/JP3768232B2/ja
Priority to NZ259880A priority patent/NZ259880A/en
Priority to CZ951879A priority patent/CZ187995A3/cs
Priority to FI953489A priority patent/FI953489A7/fi
Priority to APAP/P/1994/000613A priority patent/AP457A/en
Priority to SI9400021A priority patent/SI9400021A/sl
Priority to IL108372A priority patent/IL108372A/en
Priority to TW083104895A priority patent/TW267168B/zh
Priority to EC1994001104A priority patent/ECSP941104A/es
Priority to PE1994244634A priority patent/PE54194A1/es
Priority to HU95P/P00514P priority patent/HU211914A9/hu
Priority to NO952872A priority patent/NO305603B1/no
Priority to US08/934,540 priority patent/US5889178A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GB939301000A 1993-01-20 1993-01-20 Chemical compounds Pending GB9301000D0 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
GB939301000A GB9301000D0 (en) 1993-01-20 1993-01-20 Chemical compounds
IS4121A IS4121A (is) 1993-01-20 1994-01-14 Hliðstæð aðferð til framleiðslu á 2,6-Díamínópúrín afleiðum
APAP/P/1994/000613A AP457A (en) 1993-01-20 1994-01-18 2,6-Diaminopurine derivatives.
US08/446,727 US5925624A (en) 1993-01-20 1994-01-18 2,6-Di (substitutedamino) purine ribonucleoside analogues and administration to treat respiratory inflammation
JP51665294A JP3768232B2 (ja) 1993-01-20 1994-01-18 ２，６‐ジアミノプリン誘導体
PCT/EP1994/000145 WO1994017090A1 (en) 1993-01-20 1994-01-18 2,6-diaminopurine derivatives
AT94905100T ATE164849T1 (de) 1993-01-20 1994-01-18 1,6-diaminopurin-derivate
DE69409503T DE69409503T2 (de) 1993-01-20 1994-01-18 1,6-diaminopurin-derivate
CA002153688A CA2153688A1 (en) 1993-01-20 1994-01-18 2,6-diaminopurine derivatives
DK94905100T DK0680488T3 (da) 1993-01-20 1994-01-18 2,6-Diaminopurinderivater
EP94905100A EP0680488B1 (en) 1993-01-20 1994-01-18 2,6-diaminopurine derivatives
SK918-95A SK281229B6 (sk) 1993-01-20 1994-01-18 2,6-diaminopurínové deriváty, spôsob ich výroby, ich použitie a farmaceutické prostriedky s ich obsahom
PL94309975A PL309975A1 (en) 1993-01-20 1994-01-18 Derivatives of 2,6-diaminopurine
ES94905100T ES2117249T3 (es) 1993-01-20 1994-01-18 Derivados de 2,6-diaminopurina.
KR1019950702963A KR960700261A (ko) 1993-01-20 1994-01-18 2, 6-디아미노푸린 유도체(2,6-Diaminopurine Derivatives)
ZA94335A ZA94335B (en) 1993-01-20 1994-01-18 2,6-Diaminopurine derivatives.
AU58851/94A AU679714B2 (en) 1993-01-20 1994-01-18 2,6-diaminopurine derivatives
RU95122754A RU2129561C1 (ru) 1993-01-20 1994-01-18 ПРОИЗВОДНЫЕ 2,6-ДИАМИНОПУРИН-β-D-РИБОФУРАНУРОНАМИДА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМСОСТАВ ДЛЯ ПОДАВЛЕНИЯ АКТИВНОСТИ ЛЕЙКОЦИТОВ, СПОСОБ ЕГО ПОЛУЧЕНИЯ, СПОСОБ ПОДАВЛЕНИЯ АКТИВНОСТИ ЛЕЙКОЦИТОВ
CN94191527A CN1043997C (zh) 1993-01-20 1994-01-18 2,6-二氨基嘌呤衍生物及其用途和含该衍生物的药物组合物
NZ259880A NZ259880A (en) 1993-01-20 1994-01-18 Diaminopurine-beta-d-ribofuranuronamide derivatives and pharmaceutical compositions
CZ951879A CZ187995A3 (en) 1993-01-20 1994-01-18 2,6-diaminopurine derivatives, process of their preparation, their use for preparing pharmaceutical preparations and and pharmaceutical composition containing thereof
FI953489A FI953489A7 (fi) 1993-01-20 1994-01-18 2,6-diaminopuriinijohdannaisia
IL108372A IL108372A (en) 1993-01-20 1994-01-19 1-(2-AMINO-6- DIPHENYLETHYLAMINO-9H- PURIN-9-YL)-1- DEOXY-b-D- RIBOFURANURONAMIDE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SI9400021A SI9400021A (en) 1993-01-20 1994-01-19 2,6-diaminopurin-beta-d-ribofuranuronamide derivatives as anti-inflammatory agents
TW083104895A TW267168B (enExample) 1993-01-20 1994-05-30
EC1994001104A ECSP941104A (es) 1993-01-20 1994-06-14 Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
PE1994244634A PE54194A1 (es) 1993-01-20 1994-06-15 Derivado de 2,6-diaminopurina, procedimiento para su preparacion y composicion farmaceutica que lo contiene
HU95P/P00514P HU211914A9 (en) 1993-01-20 1995-06-28 2,6-diaminopurine derivatives
NO952872A NO305603B1 (no) 1993-01-20 1995-07-19 2,6-diaminopurin-derivater, anvendelse derav samt farmas°ytisk blanding
US08/934,540 US5889178A (en) 1993-01-20 1997-09-22 2-6-diaminopurine precursors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939301000A GB9301000D0 (en) 1993-01-20 1993-01-20 Chemical compounds

Publications (1)

Publication Number Publication Date
GB9301000D0 true GB9301000D0 (en) 1993-03-10

Family

ID=10728948

Family Applications (1)

Application Number Title Priority Date Filing Date
GB939301000A Pending GB9301000D0 (en) 1993-01-20 1993-01-20 Chemical compounds

Country Status (29)

Country Link
US (2) US5925624A (enExample)
EP (1) EP0680488B1 (enExample)
JP (1) JP3768232B2 (enExample)
KR (1) KR960700261A (enExample)
CN (1) CN1043997C (enExample)
AP (1) AP457A (enExample)
AT (1) ATE164849T1 (enExample)
AU (1) AU679714B2 (enExample)
CA (1) CA2153688A1 (enExample)
CZ (1) CZ187995A3 (enExample)
DE (1) DE69409503T2 (enExample)
DK (1) DK0680488T3 (enExample)
EC (1) ECSP941104A (enExample)
ES (1) ES2117249T3 (enExample)
FI (1) FI953489A7 (enExample)
GB (1) GB9301000D0 (enExample)
HU (1) HU211914A9 (enExample)
IL (1) IL108372A (enExample)
IS (1) IS4121A (enExample)
NO (1) NO305603B1 (enExample)
NZ (1) NZ259880A (enExample)
PE (1) PE54194A1 (enExample)
PL (1) PL309975A1 (enExample)
RU (1) RU2129561C1 (enExample)
SI (1) SI9400021A (enExample)
SK (1) SK281229B6 (enExample)
TW (1) TW267168B (enExample)
WO (1) WO1994017090A1 (enExample)
ZA (1) ZA94335B (enExample)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA000963B1 (ru) * 1995-05-30 2000-08-28 Рон-Пуленк Роре С.А. Производные 2-азабицикло[2.2.1]гептана, способ их получения и их применение
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
JP3861413B2 (ja) * 1997-11-05 2006-12-20 ソニー株式会社 情報配信システム、情報処理端末装置、携帯端末装置
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
UA62996C2 (en) * 1998-02-26 2004-01-15 Aventic Pharmaceuticals Inc 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines
US6878716B1 (en) 1998-06-02 2005-04-12 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CA2334200C (en) 1998-06-02 2011-01-25 Cadus Pharmaceutical Corporation Pyrrolo[2,3d]pyrimidine compositions and their use
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
EE200000768A (et) * 1998-06-23 2002-04-15 Glaxo Group Limited 2-(puriin-9-üül)tetrahüdrofuraan-3,4-diooli derivaadid
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
RU2258071C2 (ru) * 1999-05-24 2005-08-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
IL150062A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Proton pump inhibitors
EP1939203B1 (en) * 2000-04-25 2014-11-19 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
EA008241B1 (ru) * 2000-04-25 2007-04-27 Айкос Корпорейшн Ингибиторы фосфатидилинозитол-3-киназы дельта человека
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6861524B2 (en) 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
WO2002088079A2 (en) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
DK1406667T3 (da) * 2001-07-06 2008-06-16 Topigen Pharmaceuticals Inc Fremgangsmåder til at öge oligonukleotiders in vivo-effektivitet og hæmme inflammation hos pattedyr
IL161867A0 (en) * 2001-11-09 2005-11-20 Cv Therapeutics Inc A2b adenosine receptor antagonists
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
DE60234376D1 (de) 2001-11-27 2009-12-24 Anadys Pharmaceuticals Inc 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung
EP2050751A1 (en) 2001-11-30 2009-04-22 OSI Pharmaceuticals, Inc. Compounds specific to adenosine A1 and A3 receptors and uses thereof
CN1816551A (zh) 2001-12-20 2006-08-09 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物,它们的合成及用途
US6916804B2 (en) 2001-12-20 2005-07-12 Osi Pharmaceuticals, Inc. Pyrimidine A2b selective antagonist compounds, their synthesis and use
ES2237234B1 (es) * 2002-08-02 2006-11-01 Universidad De Oviedo Preparacion de (+) y (-)-trans-ciclopentano-1,2-diamina.
US7022681B2 (en) * 2002-08-15 2006-04-04 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0328319D0 (en) * 2003-12-05 2004-01-07 Cambridge Biotechnology Ltd Improved synthesis of 2-substituted adenosines
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
CN103087133B (zh) * 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
FR2874014B1 (fr) * 2004-08-03 2010-05-14 Univ Paris Descartes Analogues d'aminoglycosides, leur utilisation et leur synthese
RU2416412C2 (ru) 2004-10-29 2011-04-20 Топиджен Фармасьютикалз Инк. Антисмысловые олигонуклеотиды для лечения аллергии и пролиферации неопластических клеток
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
BRPI0518861B8 (pt) 2004-12-17 2021-05-25 Anadys Pharmaceuticals Inc compostos, sais ou hidratos farmaceuticamente aceitos, composição farmacêutica e uso de quantidade terapeutica ou profilaticamente eficaz de composto ou de composição farmacêutica
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR20130020850A (ko) 2005-10-21 2013-02-28 노파르티스 아게 Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
JP5117391B2 (ja) 2005-11-21 2013-01-16 アナディス ファーマシューティカルズ インク ５−アミノ−３Ｈ−チアゾロ［４，５−ｄ］ピリミジン−２−オンを調製するための新規な方法
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ATE496924T1 (de) 2006-06-22 2011-02-15 Anadys Pharmaceuticals Inc Prodrugs von 5-amino-3-(3'-deoxy-beta-d- ribofuranosyl)-thiazolä4,5-düpyrimidin-2,7-dion
WO2008011406A2 (en) 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
AU2007315234A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
EP2192905A4 (en) 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
US8431578B2 (en) 2008-01-11 2013-04-30 Novartis Ag Organic compounds
ES2331867B1 (es) * 2008-07-17 2010-10-27 Entrechem, S.L. Sintesis enzimatica de derivados enantiomericamente enriquecidos de trans-ciclopentano- 1,2-diaminas.
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CA2743642C (en) 2008-11-13 2017-09-19 Calistoga Pharmaceuticals, Inc. Therapies for hematologic malignancies
HRP20121006T1 (hr) 2009-01-29 2013-01-31 Novartis Ag Supstituirani benzimidazoli za lijeäśenje astrocitoma
JP2012521994A (ja) 2009-03-24 2012-09-20 ギリアード カリストガ エルエルシー ２−プリニル−３−トリル−キナゾリノン誘導体のアトロプ異性体および使用方法
CA2759724A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
ES2709108T3 (es) 2009-08-17 2019-04-15 Intellikine Llc Compuestos heterocíclicos y usos de los mismos
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
MX2012008049A (es) 2010-01-12 2012-08-01 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
BR112014021935A2 (pt) 2012-03-05 2019-09-24 Gilead Calistoga Llc formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
DK2822954T3 (en) 2012-12-21 2016-05-30 Gilead Sciences Inc POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
NO2865735T3 (enExample) 2013-07-12 2018-07-21
SMT201700498T1 (it) 2013-07-12 2017-11-15 Gilead Sciences Inc Composti di carbamoilpiridone policiclici e loro uso per il trattamento di infezioni da hiv
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
EA201690990A1 (ru) 2013-12-20 2016-11-30 Джилид Калистога Ллс Способы получения ингибиторов фосфатидилинозитол-3-киназы
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (enExample) 2014-06-20 2018-06-23
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
WO2018030184A1 (ja) * 2016-08-10 2018-02-15 株式会社スリーボンド エポキシ樹脂組成物およびこれを含む導電性接着剤
CN106632339B (zh) * 2016-12-16 2018-11-27 温州医科大学 一种6-取代-9h-嘌呤类衍生物及其制备方法和应用
WO2019152977A2 (en) 2018-02-05 2019-08-08 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
CN119798352B (zh) * 2024-01-15 2025-11-11 中国医学科学院药物研究所 化合物yzg-331的晶型及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE789773A (fr) * 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
CA1239397A (en) * 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
DE3576344D1 (de) * 1984-04-18 1990-04-12 Whitby Research Inc Cardio-vasodilatatore n-6-substituierte adenosine.
US4663313A (en) * 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US4757747A (en) * 1986-04-08 1988-07-19 Vickers, Incorporated Power transmission
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
EP0277917A3 (en) * 1987-02-04 1990-03-28 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives
DE3810551A1 (de) * 1987-04-06 1988-11-03 Sandoz Ag Neue ribofuranuronsaeure-derivate
US5219840A (en) * 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
LU87181A1 (fr) * 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
DE68924319T2 (de) * 1988-03-16 1996-05-15 Scripps Research Inst Als therapeutische mittel verwendbare substituierte adeninderivate.
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
CA2028002A1 (en) * 1989-10-19 1991-04-20 Daniel P. Becker Method of treating gastrointestinal motility disorders
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
DE4025879A1 (de) * 1990-08-16 1992-02-20 Sandoz Ag Neue adenosin derivate, deren herstellung und verwendung
FR2687678B1 (fr) * 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
EP0708781B1 (en) * 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists

Also Published As

Publication number Publication date
ES2117249T3 (es) 1998-08-01
EP0680488A1 (en) 1995-11-08
WO1994017090A1 (en) 1994-08-04
IS4121A (is) 1994-07-21
JPH08505864A (ja) 1996-06-25
PL309975A1 (en) 1995-11-13
DE69409503D1 (de) 1998-05-14
ZA94335B (en) 1994-10-24
HU211914A9 (en) 1996-01-29
IL108372A0 (en) 1994-04-12
PE54194A1 (es) 1995-01-06
SI9400021A (en) 1994-09-30
CN1043997C (zh) 1999-07-07
NZ259880A (en) 1996-11-26
DE69409503T2 (de) 1998-08-06
AU5885194A (en) 1994-08-15
KR960700261A (ko) 1996-01-19
CA2153688A1 (en) 1994-08-04
ATE164849T1 (de) 1998-04-15
CZ187995A3 (en) 1996-01-17
NO952872L (no) 1995-09-13
CN1119440A (zh) 1996-03-27
US5889178A (en) 1999-03-30
SK91895A3 (en) 1996-04-03
NO952872D0 (no) 1995-07-19
SK281229B6 (sk) 2001-01-18
NO305603B1 (no) 1999-06-28
FI953489L (fi) 1995-09-13
AU679714B2 (en) 1997-07-10
DK0680488T3 (da) 1999-01-25
IL108372A (en) 1998-06-15
ECSP941104A (es) 1994-12-15
FI953489A0 (fi) 1995-07-19
US5925624A (en) 1999-07-20
RU2129561C1 (ru) 1999-04-27
EP0680488B1 (en) 1998-04-08
AP457A (en) 1996-02-01
AP9400613A0 (en) 1994-01-31
JP3768232B2 (ja) 2006-04-19
FI953489A7 (fi) 1995-09-13
TW267168B (enExample) 1996-01-01

Similar Documents

Publication Publication Date Title
GB9304618D0 (en) Chemical compounds
GB9301000D0 (en) Chemical compounds
GB9312210D0 (en) Chemical compounds
GB9310635D0 (en) Chemical compounds
GB9305469D0 (en) Chemical compounds
GB2280677B (en) Chemical compounds
GB9308421D0 (en) Chemical compounds
GB9305509D0 (en) Chemical compounds
GB9305523D0 (en) Chemical compounds
GB9305510D0 (en) Chemical compounds
GB9305459D0 (en) Chemical compounds
GB9306941D0 (en) Chemical compounds
GB9303987D0 (en) Chemical compounds
GB9300882D0 (en) Chemical compounds
GB9304530D0 (en) Chemical compounds
GB9303903D0 (en) Chemical compounds
GB9304640D0 (en) Chemical compounds
GB9304641D0 (en) Chemical compounds
GB9304642D0 (en) Chemical compounds
GB9303902D0 (en) Chemical compounds
GB9303572D0 (en) Chemical compounds
GB9302844D0 (en) Chemical compounds
GB9302801D0 (en) Chemical compounds
GB9302800D0 (en) Chemical compounds
GB9301092D0 (en) Chemical compounds